It has been shown that epidermal growth factor receptor (EGFR), the prototypical growth factor receptor tyrosine kinase (RTK)3, is one of the most important key players in the development of many lethal cancers globally4,5 including: colorectal cancers, ovarian cancers6, breast cancers7, and non-small-cell lung cancers (NSCLC) in which EGFR overexpression takes place in approximately 43–89% of all cases and relates with diminutive survival and chemoresistance.8 This evidence concerns the gene EGFR and colorectal cancer.